S. Halabi

发表

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses

L. Collette, M. Sydes, M. Regan, 2019, JNCI cancer spectrum.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

P. Kantoff, L. Collette, M. Sydes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

J. Baron, R. Sandler, R. Benamouzig, 2009, Journal of the National Cancer Institute.

On model specification and selection of the Cox proportional hazards model

S. Halabi, Chen-Yen Lin, 2013, Statistics in medicine.

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

E. Winer, R. Schilsky, C. Hudis, 2011, European journal of cancer.

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

M. Somerfield, K. Anderson, S. Jagannath, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

E. Winer, S. Edge, C. Shapiro, 2010, Journal of the National Cancer Institute.

Factor V l eiden Mutation and t hromboembolism r isk in Women r eceiving Adjuvant t amoxifen for Breast c ancer

E. Winer, S. Edge, C. Shapiro, 2010 .

Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology.

S. Halabi, Cai Li, S. Luo, 2019, JCO precision oncology.

Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

E. Small, B. Rini, W. Stadler, 2014, Cancer.

Comparison of regression imputation methods of baseline covariates that predict survival outcomes

Y. Lokhnygina, S. Halabi, Nicole C Solomon, 2020, Journal of Clinical and Translational Science.

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

P. Kantoff, E. Small, B. Woda, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs

R. Schilsky, S. Nass, H. Moses, 2019, The oncologist.

The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).

P. Kantoff, N. Keating, B. Mahal, 2015, Journal of the National Cancer Institute.

Comparison of futility monitoring guidelines using completed phase III oncology trials

B. Freidlin, E. Korn, S. Mandrekar, 2017, Clinical trials.

The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480

P. Kantoff, E. Small, N. Vogelzang, 2005, Clinical Cancer Research.

The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone.

R. J. Lee, S. Halabi, A. Hussain, 2019, Critical reviews in oncology/hematology.

Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup

B. Freidlin, H. Scher, W. Oh, 1999 .

Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, C. Calfa, E. Garrett-Mayer, 2020, JCO precision oncology.

Risk Models for Individualized Prognosis in the Practice of Precision Oncology

C. Compton, M. Kattan, D. Sargent, 2017 .

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.

P. Kantoff, E. Small, N. Vogelzang, 2005, Urology.

On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve.

Aiyi Liu, S. Halabi, Hua Ma, 2019, Journal of probability and statistics.

Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma

J. Hainsworth, L. Pickering, A. Armstrong, 2021, Clinical Cancer Research.

Residential metal contamination and potential health risks of exposure in adobe brick houses in Potosí, Bolivia.

J. Vandenberg, D. Richter, H. Hsu-Kim, 2016, The Science of the total environment.

Penalized weighted proportional hazards model for robust variable selection and outlier detection

Xiaoli Gao, S. Halabi, Bin Luo, 2022, Statistics in medicine.

Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.

A. Armstrong, D. George, M. Goodin, 2015, Urologic oncology.

Anthropometric Measurements and Epithelial Ovarian Cancer Risk in African–American and White women

A. Berchuck, R. Bentley, J. Schildkraut, 2005, Cancer Causes & Control.

Transforming growth factor β receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk

J. Marks, A. Berchuck, S. Murphy, 2005 .

Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.

A. Berchuck, E. Iversen, R. Bentley, 2008, American journal of epidemiology.

Factorial Trials

S. Piantadosi, S. Halabi, 2021, Principles and Practice of Clinical Trials.

Advancing Precision Oncology Through Biomarker-Driven Trials: Theory vs. Practice

D. Niedzwiecki, S. Halabi, 2019, CHANCE.

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.

W. Oh, M. Regan, N. Kikuno, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma

W. Oh, E. Small, N. Vogelzang, 2003, Cancer.

Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer.

I. Tannock, I. Thompson, C. Tangen, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Recruiting older women for screening mammography.

S. Vernon, V. Vogel, S. Halabi, 1993, Cancer detection and prevention.

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.

A. Kishan, R. Mehra, H. Sandler, 2021, The Lancet. Oncology.

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.

K. Anderson, Nofisat Ismaila, S. Jagannath, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

M. Morris, J. Moul, E. Small, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors associated with perceived risk of breast cancer among women attending a screening program

S. Vernon, M. Bondy, V. Vogel, 1993, Breast Cancer Research and Treatment.

A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events

R. Potthoff, S. Halabi, R. F. Potthoff, 2015, Pharmaceutical statistics.

Sample size selection in clinical trials when population means are subject to a partial order: one-sided ordered alternatives

M. Schell, Bahadur Singh, S. Halabi, 2008 .

ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary.

M. Somerfield, K. Anderson, S. Jagannath, 2007, Journal of oncology practice.

Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.

E. Small, N. Vogelzang, S. Halabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.

P. Kantoff, E. Small, D. Hayes, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Susan Halabi, Electra Paskett, R. Schilsky, 2003, The New England journal of medicine.

Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.

Christopher F. Martin, J. Woosley, R. Sandler, 2008, American journal of epidemiology.

Contribution Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer in Whites and African Americans

Christopher F. Martin, J. Woosley, R. Sandler, 2008 .

Breast cancer screening behaviors and attitudes in three racial/ethnic groups

S. Vernon, V. Vogel, S. Halabi, 1992, Cancer.

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

E. Small, N. Vogelzang, A. Hussain, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age at Natural Menopause and the Risk of Epithelial Ovarian Cancer

A. Whittemore, P. Hartge, G. Cooper, 2001, Obstetrics and gynecology.

A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.

P. Kantoff, M. Morris, E. Small, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.

D. Gertig, A. Berchuck, A. Spurdle, 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis.

M. Spitz, T. Hsu, S. Halabi, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Susan Halabi, Ethan Basch, P. Kantoff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

S. Gregory, H. Scher, Jun Luo, 2021, Clinical Cancer Research.

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

M. Gonen, H. Scher, J. Luo, 2021, European Journal of Cancer.

Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.

S. Halabi, J. Tierney, L. Rydzewska, 2019, European urology focus.

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

P. Kantoff, P. Nelson, M. Gleave, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Making progress on progression in metastatic prostate cancer.

A. Armstrong, S. Halabi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.

A. Armstrong, E. Small, O. Sartor, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

E. Small, Y. Whang, J. Picus, 2011, Cancer.

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer

W. Oh, A. Armstrong, T. Dorff, 2021, Prostate Cancer and Prostatic Diseases.

Daily aspirin may reduce the risk of colorectal adenoma in people with a history of colorectal cancer

S. Halabi, 2003 .

Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study

P. Kantoff, E. Small, N. Vogelzang, 2007, Clinical Cancer Research.

Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

E. Small, B. Rini, W. Stadler, 2015, Cancer.

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy

C. Collins, J. Eastham, M. Gleave, 2017, Clinical Cancer Research.

The short-term impact of tailored mammography decision-making interventions.

G P Samsa, B. Rimer, G. Samsa, 2001, Patient education and counseling.

Confusion about mammography: prevalence and consequences.

B. Rimer, S. Halabi, I. Lipkus, 1999, Journal of women's health & gender-based medicine.

Analgesic Drug Use and Risk of Ovarian Cancer

A. Berchuck, J. Schildkraut, P. Moorman, 2006, Epidemiology.

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

A. Berchuck, J. Lancaster, R. Wenham, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Oncology clinical trials

P. Müller, T. Lai, G. Rosner, 2013 .

Menopausal hormones and risk of ovarian cancer.

A. Berchuck, J. Schildkraut, P. Moorman, 2005, American journal of obstetrics and gynecology.

The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer

I. Tannock, Alison Martin, M. Morris, 2007 .

Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials

Satrajit Roychoudhury, R. Chappell, K. Anderson, 2022, JAMA oncology.

Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.

M. Morris, M. Taplin, C. Ryan, 2019, Clinical genitourinary cancer.

Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial

N. Petrelli, J. Baron, R. Sandler, 2001, Cancer.

Phase II study of high‐dose fish oil capsules for patients with cancer‐related cachexia

E. Paskett, R. Hohl, J. Atkins, 2004, Cancer.

Null Results in Brief No Relationship between Ovarian Cancer Risk and Progesterone Receptor Gene Polymorphism in a Population-based, Case-Control Study in North Carolina 1

A. Berchuck, J. Lancaster, R. Wenham, 2003 .

The Texas Breast Screening Project: Part II: Demographics, Risk Profiles, and Health Practices of Participants

V. Vogel, S. Halabi, M. Bondy, 1993, Southern medical journal.

Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients.

M. Spitz, T. Hsu, M. Bondy, 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Androgen R eceptor M utations i n A ndrogen-Indepen dent Prostate C ancer: C ancer a nd L eukemia G roup B S tudy 9 663

P. Kantoff, E. Small, B. Woda, 2003 .

Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer

Justin H Hwang, S. Halabi, N. Sharifi, 2022, Endocrine oncology.

Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges

Adrian F. Hernandez, H. Hong, N. Turner, 2022, Clinical trials.

Serum androgens: associations with prostate cancer risk and hair patterning.

M. Conaway, W. Demark-Wahnefried, S. Lesko, 1997, Journal of andrology.

Antidepressant Medication Use for and Risk of Ovarian Cancer

A. Berchuck, J. Schildkraut, P. Moorman, 2005, Obstetrics and gynecology.

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.

R. Figlin, S. Freedland, E. Small, 2022, Urologic oncology.

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

P. Kantoff, M. Kattan, E. Small, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of race on survival in men with metastatic hormone-refractory prostate cancer.

S. George, E. Small, N. Vogelzang, 2004, Urology.

Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second‐Line Hormonal Therapy (CALGB 9181)

M. Conaway, E. Small, N. Vogelzang, 2001 .

HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182

P. Kantoff, E. Winer, M. Conaway, 1999 .

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

H. Scher, E. Antonarakis, D. Nanus, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to B. Rini et al and S. Buti et al.

T. Choueiri, M. Morris, S. Halabi, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.

R. Schilsky, E. Garrett-Mayer, S. Halabi, 2020 .

Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480.

P. Kantoff, W. Sellers, E. Small, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.

E. Small, B. Rini, W. Stadler, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Omar H. Butt, Alokkumar Jha, M. Bonnen, 2020, Cancer Cell.

Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.

J. Hainsworth, L. Pickering, A. Armstrong, 2021, Kidney cancer journal : official journal of the Kidney Cancer Association.

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

M. Sydes, M. Gleave, R. Eeles, 2022, European urology.

Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable‐risk localized prostate cancer

M. Zelefsky, E. Small, J. Bogart, 2008, Cancer.

Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19

C. Connell, J. Warner, T. Choueiri, 2021, JAMA network open.

Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782.

E. Small, J. Picus, N. Vogelzang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer

M. Harrison, A. Armstrong, I. Spasojević, 2022, The Prostate.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

B. Freidlin, H. Scher, W. Oh, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line chemotherapy for advanced hormone-refractory prostate cancer.

O. Sartor, N. Vogelzang, S. Halabi, 2008, Clinical advances in hematology & oncology : H&O.

Are Patients With Elevated Liver Tests at Increased Risk of Drug-Induced Liver Injury?

N. Marcon, L. Ackerson, R. Sandler, 2004 .

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

M. Morris, E. Small, M. Taplin, 2019, Prostate Cancer and Prostatic Diseases.

To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence.

S. Halabi, B. Carthon, W. Kelly, 2022, JAMA oncology.

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, J. Krauss, C. Calfa, 2022, JCO precision oncology.

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.

R. Schilsky, F. Meric-Bernstam, E. Garrett-Mayer, 2022, JCO precision oncology.

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

D. Lake, E. Small, N. Vogelzang, 2000, Cancer.

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial

T. Choueiri, T. Olencki, M. Morris, 2016 .

Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.

E. Paskett, R. Hohl, V. Hárs, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).

P. Kantoff, L. Schwartz, E. Basch, 2015 .

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.

M. Morris, J. Rosenberg, K. Ballman, 2019, Journal of Clinical Oncology.

Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia

J. Vandenberg, D. Richter, H. Hsu-Kim, 2011 .

Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980

E. Winer, R. Schilsky, C. Hudis, 2008 .

Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)

A. Berchuck, J. Schildkraut, P. Moorman, 2002, Cancer Causes & Control.

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

M. Rubin, M. Sydes, M. Gleave, 2022, European urology.

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.

N. Vogelzang, V. Hárs, M. Taplin, 1999, Seminars in oncology.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Thomas Wiegel, Colin C Pritchard, Stefano Fanti, 2018, European urology.

Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

A. Armstrong, D. George, S. Halabi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

E. Small, A. Kessinger, N. Vogelzang, 2008, Clinical genitourinary cancer.

Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Edward S. Kim, Susan Halabi, Elizabeth Garrett-Mayer, 2019, JCO precision oncology.

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

D. Bajorin, E. Small, S. Halabi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer

P. Febbo, A. Jimeno, A. Partin, 2010, Clinical Cancer Research.

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

T. Choueiri, M. Michaelson, T. Olencki, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

S. Gregory, A. Armstrong, P. Giannakakou, 2021, Molecular Cancer Research.

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer

S. Gregory, C. Spritzer, A. Armstrong, 2019, PloS one.

Pan-Cancer Prognostic Models: Statistical Exercise or Clinical Tools?

S. Halabi, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.

J. Eastham, M. Gleave, H. Beltran, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The importance of identifying and validating prognostic factors in oncology.

K. Owzar, S. Halabi, 2010, Seminars in oncology.

Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.

S. Halabi, 2008, Urologic oncology.

Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer

O. Elemento, V. Pascual, A. Sboner, 2021, medRxiv.

Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

A. Wyatt, T. Choueiri, M. Morris, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Title: Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer Authors:

O. Elemento, V. Pascual, A. Sboner, 2021 .

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

C. Spritzer, A. Armstrong, J. Madden, 2020, Urologic oncology.

Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer

S. Gregory, S. Tomlins, Jun Luo, 2019, Genes, chromosomes & cancer.

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

A. Armstrong, D. George, E. Yu, 2017, European journal of cancer.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Oliver Sartor, Susan Halabi, Lawrence H Schwartz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of a breast cancer risk assessment model in women with a positive family history.

E. Lustbader, M. Bondy, E. Ross, 1994, Journal of the National Cancer Institute.

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

R. Schilsky, E. Garrett-Mayer, S. Halabi, 2020, Targeted Oncology.

Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay.

P. Ye, M. Ehrlich, S. Halabi, 1995, Cancer research.

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.

P. Kantoff, E. Small, D. Hayes, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic S ignificance o f R everse T ranscriptase P olymerase Chain R eaction f or P rostate-Specifi c A ntigen i n M etastatic Prostate C ancer: A N ested S tudy W ithin C ALGB 9 583

P. Kantoff, E. Small, D. Hayes, 2003 .

Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.

M. Sydes, C. Drake, S. Fanti, 2021, European journal of cancer.

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

P. Kantoff, M. Rubin, M. Sydes, 2020, European urology.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

I. Tannock, M. Rubin, A. Chinnaiyan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia.

M. Spitz, S. Strom, M. Keating, 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Evaluation of an Epithelial Plasticity (EP) Biomarker Panel in Men with Localized Prostate Cancer

S. Freedland, A. Armstrong, R. Vollmer, 2015, Prostate Cancer and Prostatic Disease.

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.

P. Kantoff, E. Small, D. Hayes, 2001, Cancer research.

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)

G. Mayhew, M. Morris, E. Small, 2015, EBioMedicine.

Variable Selection Approaches in High-Dimensional Space

Susan Halabi, Qian Yang, Bin Luo, 2021, Emerging Topics in Statistics and Biostatistics.

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).

Ivo D. Shterev, P. Febbo, E. Small, 2013 .

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.

P. Kantoff, E. Small, D. Hayes, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

J. Hainsworth, L. Pickering, A. Armstrong, 2016, The Lancet. Oncology.

Combined performance of screening and variable selection methods in ultra-high dimensional data in predicting time-to-event outcomes

Susan Halabi, Lira Pi, S. Halabi, 2018, Diagnostic and Prognostic Research.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.

E. Small, N. Vogelzang, S. Halabi, 2006, The Journal of urology.

Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine

Thomas J. Smith, M. Nykter, T. Tammela, 2021, European urology open science.

In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions

S. Güsewell, S. Halabi, S. Gillessen, 2021, European urology open science.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

M. Terris, A. Kishan, M. Cooperberg, 2019, JAMA oncology.

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

H. Beltran, M. Morris, A. Armstrong, 2019, Journal of Clinical Oncology.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

S. Gregory, H. Scher, Jun Luo, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

I. Tannock, I. Thompson, C. Tangen, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

F. Saad, M. Morris, E. Small, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2019 .

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Susan Halabi, Ian F Tannock, Ian M Thompson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

A. D'Amico, P. Kantoff, K. Pienta, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

S. Halabi, R. Ayyagari, N. Shore, 2021, The Journal of urology.

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

I. Tannock, A. Armstrong, D. George, 2010, European journal of cancer.

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

D. Berry, A. D'Amico, P. Kantoff, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer

M. Harrison, A. Armstrong, Jiaoti Huang, 2022, Prostate Cancer and Prostatic Diseases.

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

H. Scher, A. Armstrong, D. Petrylak, 2012, European urology.

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

T. Choueiri, Y. Shyr, R. Nanchal, 2023, The Lancet Regional Health - Americas.

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine

Susan Halabi, C. Compton, M. Kattan, 2016, CA: a cancer journal for clinicians.

Critical Assessment of Clinical Prognostic Tools in Melanoma

C. Compton, K. Hess, R. Scolyer, 2016, Annals of Surgical Oncology.

Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.

M. Harrison, A. Armstrong, Jiaoti Huang, 2021 .

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer

M. Harrison, H. Scher, Jun Luo, 2020, JCO precision oncology.

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

K. Owzar, E. Small, N. Vogelzang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

P. Kantoff, M. Morris, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

E. Small, B. Rini, J. Picus, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.

E. Platz, B. Mahal, J. Simons, 2021, European urology oncology.

Quality of life outcomes for patients with metastatic castration‐resistant prostate cancer and pretreatment prognostic score

A. Morgans, S. Halabi, C. Ryan, 2023, The Prostate.

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

P. Kantoff, E. Winer, M. Conaway, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate‐risk prostate cancer

M. Kuettel, E. Small, S. DiBiase, 2011, Cancer.

Trinucleotide Repeat Polymorphisms in the Androgen Receptor Gene and Risk of Ovarian Cancer

A. Berchuck, E. Iversen, S. Murphy, 2007, Cancer Epidemiology Biomarkers & Prevention.

Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel

M. Morris, M. Taplin, C. Ryan, 2020 .

A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.

A. D'Amico, E. Small, N. Vogelzang, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer and Leukemia Group B 90206

R. Schilsky, E. Small, B. Rini, 2004, Clinical Cancer Research.

Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).

A. Armstrong, D. George, E. Yu, 2015 .

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

R. Schilsky, C. Calfa, E. Garrett-Mayer, 2020, Targeted Oncology.

Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes

C. Compton, K. Hess, M. Weiser, 2017, Journal of surgical oncology.

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.

R. Schilsky, E. Yang, E. Burgess, 2023, JCO precision oncology.

The Prostate

M. Harrison, A. Armstrong, D. George, 2019 .

Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

I. Ostrovnaya, M. Milowsky, D. Bajorin, 2013, Journal of the National Cancer Institute.

Design issues in randomized phase II/III trials.

Boris Freidlin, Susan Halabi, Edward L Korn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

S. Steinberg, H. Parnes, J. Schlom, 2010, Cancer Immunology, Immunotherapy.

Best (but oft-forgotten) practices: sample size and power calculation for a dietary intervention trial with episodically consumed foods.

Zhiwei Zhang, Aiyi Liu, T. Nansel, 2020, The American journal of clinical nutrition.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Macie J. Rubin, M. Rubin, M. Sydes, 2023, European journal of cancer.

A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer

K. Owzar, R. Kittles, M. Harrison, 2021, Cancer.

A simple method for deriving the confidence regions for the penalized Cox’s model via the minimand perturbation

Susan Halabi, Chen-Yen Lin, S. Halabi, 2017, Communications in statistics: theory and methods.

Independent data monitoring committees: an update and overview.

O. Sartor, S. Halabi, 2015, Urologic oncology.

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.

A. Armstrong, E. Small, C. Sternberg, 2013, Journal of the National Cancer Institute.

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

T. Choueiri, M. Michaelson, T. Olencki, 2018, European journal of cancer.

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Edward S. Kim, R. Schilsky, E. Voest, 2018, JCO precision oncology.

Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup

Susan Halabi, Brian Calingaert, Rex C Bentley, 2008, Cancer Epidemiology Biomarkers & Prevention.

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

A. Armstrong, D. George, M. Fleming, 2013, Clinical genitourinary cancer.

Overview of bladder cancer trials in the Cancer and Leukemia Group B

D. Bajorin, M. Edelman, E. Small, 2003, Cancer.

On the design and the analysis of stratified biomarker trials in the presence of measurement error

Aiyi Liu, S. Halabi, Chen-Yen Lin, 2021, Statistics in medicine.

Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools

C. Compton, R. Rami-Porta, L. McShane, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Can tailored interventions increase mammography use among HMO women?

B. Rimer, I. Lipkus, S. Halabi, 2000, American journal of preventive medicine.

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

K. Owzar, M. Ratain, P. Friedman, 2015, Cancer.

Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study

P. Kantoff, E. Small, B. Woda, 2005, Clinical Cancer Research.

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

E. Plimack, M. Morris, D. Bajorin, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

E. Gelmann, E. Small, W. Stadler, 2004, Urologic oncology.

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

Susan Halabi, Nicholas J Vogelzang, P. Kantoff, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.

E. Basch, A. Bennett, T. Atkinson, 2012, Pain medicine.

The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.

I. Tannock, M. Morris, A. Armstrong, 2014 .

Circulating levels of inflammatory cytokines and risk of colorectal adenomas.

John T. Woosley, Robert S. Sandler, Christopher F. Martin, 2008, Cancer research.

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

R. Schilsky, A. Alva, C. Calfa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC).

M. Morris, E. Small, S. Halabi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Score and deviance residuals based on the full likelihood approach in survival analysis

Aiyi Liu, S. Halabi, S. Dutta, 2020, Pharmaceutical statistics.

Inverse correlation between body mass index and clinical outcomes in men with advanced castration–recurrent prostate cancer

E. Small, N. Vogelzang, S. Halabi, 2007, Cancer.

A phase II study of gemcitabine and capecitabine in metastatic renal cancer

E. Small, B. Rini, M. Ernstoff, 2006, Cancer.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Ivo D. Shterev, P. Febbo, Yusuke Nakamura, 2016, Clinical Cancer Research.

Residential Mercury Contamination in Adobe Brick Homes in Huancavelica, Peru

J. Vandenberg, D. Richter, H. Hsu-Kim, 2013, PloS one.

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

T. Choueiri, M. Michaelson, M. Morris, 2019, The oncologist.

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

J. Eastham, M. Morris, J. Mohler, 2018, Prostate Cancer and Prostatic Diseases.

Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee

A. D'Amico, D. Bajorin, J. Mohler, 2006, Clinical Cancer Research.

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

M. Harrison, A. Armstrong, D. George, 2017, The Prostate.

Attitudes and Knowledge Associated with being Undecided about Hormone Replacement Therapy: Results from a Community Sample

B. Rimer, C. McBride, C. Skinner, 1999 .

A phase II trial of cisplatin, fixed dose‐rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102

D. Bajorin, E. Small, S. Halabi, 2007, BJU international.

A min–max combination of biomarkers to improve diagnostic accuracy

Chunling Liu, Aiyi Liu, Susan Halabi, 2011, Statistics in medicine.

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

J. Warner, T. Choueiri, M. Galsky, 2021, Annals of Oncology.

Epirubicin and ifosfamide in metastatic breast cancer.

S. Seeber, S. Halabi, R. Becher, 1996, Seminars in Oncology.

Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102

D. Bajorin, E. Small, S. Halabi, 2004 .

Analysis of Survival Data with Missing Measurements of a Time-Dependent Binary Covariate

B. Davis, C. Wun, S. Halabi, 2003, Journal of Biopharmaceutical Statistics.

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

E. Small, S. DiBiase, M. Hurwitz, 2008, International journal of radiation oncology, biology, physics.

Mercury hair levels and factors that influence exposure for residents of Huancavelica, Peru

J. Vandenberg, D. Richter, H. Hsu-Kim, 2015, Environmental Geochemistry and Health.

Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru.

J. Vandenberg, D. Richter, P. Heine, 2012, The Science of the total environment.

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel

I. Tannock, I. Thompson, C. Tangen, 2020, JNCI cancer spectrum.

Identification of women at increased risk for breast cancer in a population-based screening program.

E. Lustbader, M. Bondy, V. Vogel, 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

P. Kantoff, M. Morris, E. Small, 2013, Cancer.

Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.

J. Bono, A. Armstrong, E. Small, 2012 .

Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, E. Garrett-Mayer, S. Halabi, 2019 .

Effects of a mammography decision-making intervention at 12 and 24 months.

Susan Halabi, Barbara K Rimer, Isaac M Lipkus, 2002, American journal of preventive medicine.

The impact of abnormal mammograms on psychosocial outcomes and subsequent screening

B. Rimer, I. Lipkus, S. Halabi, 2000, Psycho-oncology.

A tailored intervention to aid decision-making about hormone replacement therapy.

B. Rimer, C. McBride, H. Bosworth, 2002, American journal of public health.

Factors associated with repeat mammography screening.

B. Rimer, G. Samsa, C. Skinner, 2000, The Journal of family practice.

Association between Family History Sensitivity in Upper Aerodigestive

M. Spitz, M. Bondy, S. Halabi, 1993 .

Women's interest in chemoprevention for breast cancer.

B. Rimer, M. Kuchibhatla, C. Skinner, 2001, Archives of internal medicine.

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy

E. Small, J. Picus, N. Vogelzang, 2012, Cancer.

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

H. Beltran, M. Morris, E. Antonarakis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

H. Beltran, T. Choueiri, C. Kyriakopoulos, 2022, The Journal of clinical investigation.

High Dimensional Variable Selection with Error Control

Susan Halabi, Sangjin Kim, S. Halabi, 2016, BioMed research international.

Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment

F. Saad, C. Sternberg, G. Kramer, 2009 .

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

G. Rosner, M. Ratain, David Palchak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hydrocortisone W ith o r W ithout M itoxantrone i n M en W ith Hormone-Refractory P rostate C ancer: R esults o f t he C ancer and L eukemia G roup B 9 182 S tudy

P. Kantoff, E. Winer, M. Conaway, 1999 .

Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).

M. Harrison, G. Sonpavde, M. Milowsky, 2018, Journal of Clinical Oncology.

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.

R. Schilsky, S. Nass, H. Moses, 2019, The oncologist.

Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

D. Bajorin, E. Small, S. Halabi, 2009, Clinical genitourinary cancer.

Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

R. Schilsky, E. Yang, E. Burgess, 2020, Journal of Clinical Oncology.

Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).

E. Small, W. Stadler, N. Vogelzang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

P. Kantoff, P. Humphrey, E. Small, 2006, Clinical genitourinary cancer.

Re : Carcinogenicity of the Drinking Water Mutagen 3-Chloro-4-( dichloromethyl )-5-hydroxy-2 ( 5 H )-furanone in the Rat

A. Berchuck, S. Halabi, Schildkraut, 1997 .

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy

J. Moul, P. Tran, A. Armstrong, 2015, Prostate Cancer and Prostatic Disease.

Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583.

P. Kantoff, E. Small, C. Ryan, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

M. Morris, A. Armstrong, C. Higano, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Texas Breast Screening Project: Part I: Mammographic and Clinical Results

W. P. Evans, M. Bondy, V. Vogel, 1993, Southern medical journal (Birmingham, Ala. Print).

CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC).

D. Bajorin, E. Small, J. Rosenberg, 2006, Journal of Clinical Oncology.

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

D. Bajorin, E. Small, J. Rosenberg, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102.

D. Bajorin, E. Small, S. Halabi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series

J. Eastham, M. Morris, J. Mohler, 2018, Prostate Cancer and Prostatic Diseases.

Prognostic Factors in Early‐Onset Epithelial Ovarian Cancer: A Population‐Based Study

A. Berchuck, J. Schildkraut, P. Marchbanks, 2000, Obstetrics and gynecology.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

K. Owzar, M. Ratain, P. Friedman, 2018, Clinical Cancer Research.

Title Identification of a Genomic Region between SLC 29 A 1 and HSP 90 AB 1 Associated with Risk of Bevacizumab-Induced Hypertension : CALGB 80405 ( Alliance )

K. Owzar, M. Ratain, P. Friedman, 2018 .

Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257))

I. Tannock, M. Rubin, A. Chinnaiyan, 2019 .

Low incidence of familial breast cancer among Hispanic women

M. Spitz, M. Bondy, V. Vogel, 1992, Cancer Causes & Control.

Prognostic M odel f or P redicting S urvival i n M en W ith Hormone-Refracto ry M etastatic P rostate C ancer

P. Kantoff, M. Kattan, E. Small, 2003 .

Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Philip S. Yu, Sharon S. Choi, Omar H. Butt, 2023, BMC Cancer.

LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER

J. Eastham, M. Gleave, H. Beltran, 2019, Journal of Urology.

Estimand framework: Are we asking the right questions? A case study in the solid tumor setting

A. Ravaud, R. Motzer, M. Casey, 2020, Pharmaceutical statistics.

A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detection

Susan Halabi, Sandipan Dutta, S. Halabi, 2021, Pharmaceutical statistics.

Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).

P. Kantoff, M. Morris, E. Small, 2012 .

The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.

John T. Wei, A. D'Amico, P. Schellhammer, 2010, Urology.

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

A. D'Amico, P. Kantoff, E. Small, 2008, Urology.

Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study.

M. Garcia-Blanco, A. Armstrong, D. George, 2010 .

Flexible Frames and Control Sampling in Case-Control Studies

Richard F Potthoff, Susan Halabi, Joellen M Schildkraut, 2008, The American statistician.

Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).

J. Hainsworth, L. Pickering, A. Armstrong, 2015 .

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).

J. Eastham, M. Gleave, H. Beltran, 2019, Journal of Clinical Oncology.

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.

M. Maitland, R. Schilsky, C. Drescher, 2023, JCO precision oncology.

Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.

A. Ravaud, R. Figlin, A. Pantuck, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncology clinical trials : successful design, conduct, and analysis

S. Halabi, W. Kelly, 2010 .

Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

T. Choueiri, M. Michaelson, T. Olencki, 2018, European journal of cancer.

The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.

E. Small, N. Vogelzang, S. Halabi, 2007, The Journal of urology.

LBA38Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

T. Choueiri, T. Olencki, M. Morris, 2017 .

Incidence of Autoimmune Disease in Patients after Breast Reconstruction with Silicone Gel Implants Versus Autogenous Tissue: A Preliminary Report

C. Balch, M. Miller, G. Reece, 1993, Annals of plastic surgery.

1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

M. Buyse, M. Parmar, D. Dearnaley, 2022, Annals of Oncology.

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.

A. D'Amico, C. Tempany, E. Small, 2008, International journal of radiation oncology, biology, physics.

Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).

A. Armstrong, C. Chapman, Y. Shyr, 2021 .

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

M. Sydes, M. Gleave, R. Eeles, 2022, European Urology.

Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.

C. Sweeney, W. Xie, S. Halabi, 2021 .

Detection of low level benzene exposure in supermarket wrappers by urinary muconic acid

G. Netto, S. Halabi, E. Johnson, 1999 .

Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials

B. Abella, K. Anstrom, D. Boulware, 2023, BMJ Open.

Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.

D. Bajorin, E. Small, S. Halabi, 2004, Journal of Clinical Oncology.

Circulating levels of inflammatory cytokines and risk of colorectal adenomas.

Christopher F. Martin, J. Woosley, R. Sandler, 2008, Cancer research.

Management of Patients with Advanced Prostate Cancer

P. Kantoff, I. Tannock, M. Rubin, 2018 .

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma

John D. Roberts, N. Vogelzang, J. Atkins, 2002, Cancer.

The impact of abnormal mammograms on psychosocial outcomes and subsequent screening

B. Rimer, I. Lipkus, S. Halabi, 2000, Psycho-oncology.

Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

E. Small, B. Rini, W. Stadler, 2010 .

Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).

A. Armstrong, D. George, S. Halabi, 2010 .

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration‐resistant prostate cancer

M. Harrison, A. Armstrong, S. Halabi, 2019, The Prostate.

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous

R. Schilsky, N. Petrelli, J. Baron, 2003 .

Adjusting for misclassification in a stratified biomarker clinical trial

Aiyi Liu, S. Halabi, Chunling Liu, 2014, Statistics in medicine.

Developing and Validating Prognostic Models of Clinical Outcomes

S. Halabi, Chen-Yen Lin, Lira Pi, 2019, Textbook of Clinical Trials in Oncology.

Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.

H. Scher, Jun Luo, E. Antonarakis, 2020 .

Receptor Gene and Risk of Ovarian Cancer Trinucleotide Repeat Polymorphisms in the Androgen

A. Berchuck, E. Iversen, S. Murphy, 2007 .

Sparse-Input Neural Network using Group Concave Regularization

S. Halabi, Bin Luo, 2023, ArXiv.

A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008.

E. Small, M. Ernstoff, J. Picus, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer.

E. Antonarakis, A. Armstrong, D. Danila, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer

A. Gopalan, K. Knudsen, M. Fleming, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Textbook of Clinical Trials in Oncology

S. Michiels, S. Halabi, 2019 .

Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome

B. Moser, S. Halabi, 2015, Communications in statistics: theory and methods.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

E. Small, Y. Whang, J. Picus, 2011, Cancer.

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

D. Bajorin, E. Small, S. Halabi, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer.

M. Harrison, K. Hoffman, A. Armstrong, 2020, International journal of radiation oncology, biology, physics.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

I. Tannock, M. Rubin, A. Chinnaiyan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Estimation and testing of the relative risk of disease in case‐control studies with a set of k matched controls per case with known prevalence of disease

S. Halabi, B. Moser, 2012, Statistics in medicine.

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

E. Winer, S. Edge, C. Shapiro, 2010, Journal of the National Cancer Institute.

Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)

K. Owzar, M. Ratain, S. Halabi, 2024, The pharmacogenomics journal.

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

R. Schilsky, Rui Li, A. Alva, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

P. Kantoff, I. Tannock, M. Rubin, 2018, European urology.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

I. Tannock, M. Rubin, A. Chinnaiyan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.

M. Gleave, A. Sboner, A. Wyatt, 2023, Journal of the National Cancer Institute.

Sample size determination for comparing several survival curves with unequal allocations

Bahadur Singh, S. Halabi, 2004, Statistics in medicine.

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, A. Alva, C. Calfa, 2019, Journal of Clinical Oncology.

Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

E. Small, S. Halabi, W. Kelly, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

E. Small, B. Rini, W. Stadler, 2014, Cancer.

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, F. Meric-Bernstam, M. von Mehren, 2023, JCO precision oncology.

The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer

I. Tannock, A. Armstrong, M. Eisenberger, 2008, Prostate Cancer and Prostatic Diseases.

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

C. Tangen, M. Carducci, S. Halabi, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.

T. Choueiri, T. Olencki, D. Feldman, 2018 .

ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma.

A. Armstrong, W. Stadler, Jorge A. Garcia, 2013 .

Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset?

A. Armstrong, S. Halabi, 2021, European urology.